Calithera, Antengene Announce Licensing Agreement For CB-708 In Cancer Settings

by Vandana Singh, Benzinga Editor

May 17, 2021 10:08 AM | 1 min read | Make a Comment

Calithera Biosciences Inc CALA and Antengene Corporation Ltd have announced an exclusive, worldwide license agreement for the development and commercialization of CB-708.
CB-708 is a highly potent, selective, orally-bioavailable small molecule inhibitor of CD73, currently in preclinical development for oncology.
Under the terms of the license agreement, Calithera will receive an upfront payment and potential milestone payments of up to $255 million.
Additionally, Calithera is eligible to receive tiered royalties on sales of the licensed product up to low double-digits.
Price Action: CALA shares are up 6.7% at $2.17 on the last check Monday.

Posted In: Biotech News Penny Stocks Health Care Contracts General Briefs cancer

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.